📣 Join us October 15 at Dana-Farber, in collaboration with the @lobularbca.bsky.social, for an event bringing together patients, advocates, researchers, and clinicians to raise awareness and highlight advances in #LobularBreastCancer research and care. Register today docs.google.com/forms/d/e/1F...

Join Dana-Farber experts on 🗓️ Monday, September 28th from 5-6 pm EST for Updates in the Diagnosis and Management of Inflammatory Breast Cancer for Providers. To learn more and register, please visit dfci.zoom.us/webinar/regi...

Join Dr. Ann Partridge, and Miranda McKeon for a free @bcrfcure.bsky.social webinar, “Younger Women and Breast Cancer: A Race for Answers.” 📅 Thursday, September 24 | 12 p.m. ET Learn more and register: us06web.zoom.us/webinar/regi... #BreastCancer #BreastCancerInYoungWomen

Join us Sept. 22 in Boston for the OncLive State of the Science Summit on #BreastCancer. This free, in-person meeting is designed for academic & community-based physicians and health care professionals. Register today: www.onclive.com/events

Join Dr. Ann Partridge and the Young & Strong community for a day of support, education, and connection at the 2026 Young & Strong Forum. 📅 Oct. 30 | 8:30 a.m.–5:30 p.m. 📍 InterContinental Boston 🎟️ Free to attend youngandstrong.dana-farber.org/2026-forum/

Check out this wonderful profile of Dr. Ann Partridge in @newbedfordlight.bsky.social , reflecting on her extraordinary career advancing #BreastCancer care and research, her commitment to young patients, and life as New Bedford’s “first lady.” newbedfordlight.org/dr-ann-partr...

We are leading a new study to evaluate the safety and effectivenessof a new drug known as #Avutometinib (#Avmapki®) in combinationwith the drugs #abemaciclib (Verzenio®) and #fulvestrant(Faslodex®) in metastatic hormone receptor-positive and HER2-negative (HR+/HER2-) #BreastCancer.​

Join breast oncologist Kristina Fanucci, MD, MHS, on 🗓️ September 17, 12–1 PM for an overview of invasive lobular carcinoma (ILC) breast cancer. Learn about ILC and the latest research advancing treatments for patients with ILC. Register: dfci.zoom.us/webinar/regi...

Join Dana-Farber experts on 🗓️ Monday, September 28th from 5-6 pm EST for Updates in the Diagnosis and Management of Inflammatory Breast Cancer for Providers. To learn more and register, please visit dfci.zoom.us/webinar/regi...

Join us in-person for a day of support, education & community for #YoungAdults affected by #BreastCancer. Hear from experts and connect with others who “get it.” 🗓️ Oct. 30 | 8:30 AM–5:30 PM 📍 InterContinental Boston Register today ⬇️ youngandstrong.dana-farber.org/2026-forum/

We are now enrolling to the #ERADICATE study! This is a phase Ib/II study of #Elacestrantin combination with #TrastuzumabDeruxtecan(T-DXd) for patients with CDK4/6 inhibitor and endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic #BreastCancer.

Join Dana-Farber experts on 🗓️ Monday, September 28th from 5-6 pm EST for Updates in the Diagnosis and Management of Inflammatory Breast Cancer for Providers. To learn more and register, please visit dfci.zoom.us/webinar/regi...

Join us in-person for a day of support, education & community for #YoungAdults affected by #BreastCancer. Hear from experts and connect with others who “get it.” 🗓️ Oct. 30 | 8:30 AM–5:30 PM 📍 InterContinental Boston Register today ⬇️ youngandstrong.dana-farber.org/2026-forum/

🎙️Tune in to hear Dr. Sara Tolaney discuss new first-line treatment options for metastatic triple-negative breast cancer on the Patient From Hell podcast. #mTNBC #TNBC #BreastCancer #MBC 🎧 youtu.be/GC1Kpf3vKns?...

New First-Line Treatment: Metastatic Triple-Negative Breast Cancer with Dr. Sara Tolaney

YouTube video by Patient From Hell

youtu.be

Join us Sept. 22 in Boston for the OncLive State of the Science Summit on #BreastCancer. This free, in-person meeting is designed for academic & community-based physicians and health care professionals. Register today: www.onclive.com/events

In this episode of #BreastCancerBreakthroughs, Dr. Harold Burstein and Dr. Ana Garrido-Castro discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer. youtu.be/bIbDHoaWczc?...

2026 ASCO Breast Cancer Highlights: PANKU-Breast02 | Dana-Farber Cancer Institute

YouTube video by Dana-Farber Cancer Institute

youtu.be

Join the EMBRACE Program for a day of wellness, education, and community building. The free event is open to adults living with #MetastaticBreastCancer and loved ones. #MBC 🗓️ Wednesday, September 9 | 10 a.m. - 3:30 p.m. ET 📍 Dana-Farber Cancer Institute redcapdfci.dfci.harvard.edu/redcap/surve...

Check out this #BreastCancerBreakthroughs episode, where Dr. Harold Burstein and Dr. Adrienne Waks discuss the new Neo-Healer trial in HER2-positive breast cancer, presented at #ASCO2026. youtu.be/PsWBOCZVn2g?...

2026 ASCO Breast Cancer Highlights: Neo-Healer | Dana-Farber Cancer Institute

YouTube video by Dana-Farber Cancer Institute

youtu.be

In this episode of #BreastCancerBreakthroughs, Dr. Harold Burstein and Dr. Erica Mayer discuss key updates from #ASCO2026 on the #persevERA trial and oral #SERDs for metastatic breast cancer. youtu.be/QKS1MZoQSEw?...

2026 ASCO Breast Cancer Highlights: persevERA | Dana-Farber Cancer Institute

YouTube video by Dana-Farber Cancer Institute

youtu.be

Join breast oncologist Kristina Fanucci, MD, MHS, on 🗓️ September 17, 12–1 PM for an overview of invasive lobular carcinoma (ILC) breast cancer. Learn about ILC and the latest research advancing treatments for patients with ILC. Register: dfci.zoom.us/webinar/regi...

In this #BreastCancerBreakthroughs video, Dr.Harold Burstein and Dr. Laura Dominici discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery. youtu.be/tTDzYwCI4N8?...

2026 ASCO Breast Cancer Highlights: SENOMAC | Dana-Farber Cancer Institute

YouTube video by Dana-Farber Cancer Institute

youtu.be

In this #BreastCancerBreakthroughs video, Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD, discuss new antibody drug conjugate treatment options in first line triple negative breast cancer. youtu.be/lU9DsO1fNic?...

2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer | Dana-Farber Cancer Institute

YouTube video by Dana-Farber Cancer Institute

youtu.be

In this episode of #BreastCancerBreakthroughs #ASCO2026 Highlight, Dr. Harold Burstein and Dr. Rachel Freedman discuss new research on #FoodAccess and poverty among patients with #MetastaticBreastCancer, plus Dana-Farber’s new food pantry and the role of patient navigators. youtu.be/wLhLf8U14WE?...

2026 ASCO Breast Cancer Highlights: Food Access, Poverty, and MBC | Dana-Farber Cancer Institute

YouTube video by Dana-Farber Cancer Institute

youtu.be

Join the EMBRACE Program for a day of wellness, education, and community building. The free event is open to adults living with #MetastaticBreastCancer and loved ones. #MBC 🗓️ Wednesday, September 9 | 10 a.m. - 3:30 p.m. ET 📍 Dana-Farber Cancer Institute redcapdfci.dfci.harvard.edu/redcap/surve...

🎥 Check out this #BreastCancerBreakthroughs #ASCO2026 Highlight, where Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD, discuss new research from the Breast Cancer Weight Loss (#BWEL) trial, as well as recommendations for lifestyle, diet and GLP1 agonists. youtu.be/X_oeYtPeAhE?...

2026 ASCO Breast Cancer Highlights: BWEL | Dana-Farber Cancer Institute

YouTube video by Dana-Farber Cancer Institute

youtu.be

We are now enrolling to the #CAPELA study! This is a new phase II multi-center open-label randomized study of #CAPecitabine in combination with #ELAcestrant versus capecitabine alone in advanced estrogen receptor-positive #BreastCancer.

In this short #BreastCancerBreakthroughs #ASCO2026 Highlight, Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the #HER2Climb-05 trial and how it impacts treatment for HER2+ #MetastaticBreastCancer. youtu.be/1DNsWW9s1t0?...

2026 ASCO Breast Cancer Highlights: HER2CLIMB-05 | Dana-Farber Cancer Institute

YouTube video by Dana-Farber Cancer Institute

youtu.be

Join breast oncologist Kristina Fanucci, MD, MHS, on 🗓️ September 17, 12–1 PM for an overview of #InvasiveLobularCarcinoma (ILC) #BreastCancer. Learn about ILC and the latest research advancing treatments for patients with ILC. Register: dfci.zoom.us/webinar/regi...

Join Dana-Farber experts on 🗓️ Monday, September 28th from 5-6 pm EST for Updates in the Diagnosis and Management of Inflammatory Breast Cancer for Providers. To learn more and register, please visit dfci.zoom.us/webinar/regi...

Tune in to the WEEI/NESN Jimmy Fund Radio-Telethon today for more inspiring stories from patients and the community! Donate to #KCANCER 👉 danafarber.jimmyfund.org/site/TR?fr_i...

Help strike out cancer | Jimmy Fund Radio-Telethon

Tune in August 17 and 18 and support the Jimmy Fund.

danafarber.jimmyfund.org